← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue increased 115.6% to $4.1M, while Net income increased 17.2% to ($50.2M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $4.1MWatch
- Profitability — Net income ($50.2M)Watch
- Cash generation — Free cash flow ($25.4M)Note
- Accounting — Formula distress score · no manipulation flag · earnings quality safeWatch
- Insiders — 7 buys; 0 sells in 365 daysOK
- Capital — Comparable payout data unavailableNote
Business
Insight Molecular Diagnostics Inc.: We also rebranded our kitted research use only assay, GraftAssure, as "GraftAssureIQ," and our future kitted clinical assay as "GraftAssureDx." 2 INDUSTRY AND MARKET DATA This Report contains market data and industry forecasts that were obtained from industry publications, third party market research and publicly available information.
Where the revenue comes from
Fiscal 2025, as Insight Molecular Diagnostics Inc. reports it. History and quarterly detail are in the app.
- Laboratory Services$4.0M
- Kitted Products$24K
Leadership changes
From Insight Molecular Diagnostics Inc.'s own filings, the day they're filed.
- Andrea James · Chief Financial Officer · appointmenteff. 2024-06-17
- Axon Enterprise · President · appointment
- Base Salary · departure
Latest filings
- 10-Q · Quarterly report2026-08-10
- 8-K · Company announcement2026-08-10
- 8-K · Company announcement2026-06-17
- 8-K · Company announcement2026-05-13
- 10-Q · Quarterly report2026-05-13
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Insight Molecular Diagnostics Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.